Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

0.7150
-0.0008-0.11%
Post-market: 0.73000.0150+2.10%18:37 EDT
Volume:99.23K
Turnover:71.80K
Market Cap:2.41M
PE:-0.05
High:0.7400
Open:0.7400
Low:0.7055
Close:0.7158
52wk High:480.00
52wk Low:0.7055
Shares:3.37M
Float Shares:3.37M
Volume Ratio:0.97
T/O Rate:2.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.8013
EPS(LYR):-303.4772
ROE:-106.98%
ROA:-53.08%
PB:0.19
PE(LYR):0.00

Loading ...

Clearmind Medicine wins US patent for MEAI-based binge behavior regulators

Reuters
·
Jun 18

HRT Financial LP sells 3,183 Clearmind Medicine common shares for $10,567.56

Reuters
·
Jun 18

HRT Financial LP disposes of 2,102 Clearmind Medicine common shares worth $7,062.72

Reuters
·
Jun 16

BRIEF-Clearmind Medicine Completes Dosing For Part A Of Its Of FDA-Regulated Phase I/Ii Clinical Trial

Reuters
·
Jun 16

Clearmind Medicine Completes Dosing in First 4 Cohorts of Phase I/II Alcohol Use Disorder Trial

MT Newswires Live
·
Jun 16

Clearmind completes Part A dosing in Phase I/II CMND-100 trial for alcohol use disorder

Reuters
·
Jun 16

Clearmind Medicine Completes Dosing for Part a of Its of FDA-Regulated Phase I/Ii Clinical Trial

THOMSON REUTERS
·
Jun 16

Clearmind Medicine says HRT Financial files initial beneficial ownership statement

Reuters
·
Jun 13

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:26 AM

Reuters
·
Jun 08

Clearmind Medicine spotlights new CMND-100 alcohol use disorder trial data in June 10 webinar

Reuters
·
Jun 05

Clearmind Medicine to Feature New Insights From Cmnd-100 Psychedelic Clinical Trial on “Inside Meai” Webinar

THOMSON REUTERS
·
Jun 05

Clearmind Medicine to Feature New Insights from CMND-100 Psychedelic Clinical Trial on “Inside MEAI” Webinar

GlobeNewswire
·
Jun 05

Clearmind Medicine to sell $1.5 million in convertible promissory notes at 90% of face value

Reuters
·
Jun 02

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:27 AM

Reuters
·
Jun 01

Top Premarket Decliners

MT Newswires Live
·
Jun 01

Clearmind Medicine files Japanese patent application for 5-Methoxy-2-aminoindan

TIPRANKS
·
May 29

Clearmind Medicine files Japanese patent application for MEAI-based depression treatment

Reuters
·
May 29

Clearmind Medicine announces JHM-IRB approval to advance CMND-100 trial

TIPRANKS
·
May 26

Clearmind says Johns Hopkins IRB clears next stages of CMND-100 Phase I/II trial

Reuters
·
May 26

Clearmind Medicine Announces Johns Hopkins Irb Approval to Advance Cmnd-100 Phase I/Ii Clinical Trial to the Next Parts

THOMSON REUTERS
·
May 26